港股异动 | 百济神州(06160)涨6% 替雷利珠成功递交第10项国内上市申请

智通财经2022-06-22

智通财经APP获悉，百济神州(06160)盘初高开高走，升超6%。公司宣布，NMPA已受理百泽安®（替雷利珠单抗）联合化疗，用于一线治疗肿瘤表达PD-L1的晚期或转移性胃或胃食管结合部（G/GEJ）腺癌患者的新适应症上市许可申请（sBLA）。这也是是百泽安®在中国递交的第10项上市许可申请。截至发稿，百济神州涨5.82%，报97.30港元，成交额0.48亿港元。6月21日，百济神州(06160)...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2245267136?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-06-22 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2245267136","market":"hk","top_or_hot":-1,"title":"港股异动 | 百济神州(06160)涨6% 替雷利珠成功递交第10项国内上市申请","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，百济神州(06160)盘初高开高走，升超6%。公司宣布，NMPA已受理百泽安®（替雷利珠单抗）联合化疗，用于一线治疗肿瘤表达PD-L1的晚期或转移性胃或胃食管结合部（G/GEJ）腺癌患者的新适应症上市许可申请（sBLA）。这也是是百泽安®在中国递交的第10项上市许可申请。截至发稿，百济神州涨5.82%，报97.30港元，成交额0.48亿港元。6月21日，百济神州(06160)...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/742489.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 百济神州(06160)涨6% 替雷利珠成功递交第10项国内上市申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 百济神州(06160)涨6% 替雷利珠成功递交第10项国内上市申请\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-22 09:40 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/742489.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，百济神州(06160)盘初高开高走，升超6%。公司宣布，NMPA已受理百泽安®（替雷利珠单抗）联合化疗，用于一线治疗肿瘤表达PD-L1的晚期或转移性胃或胃食管结合部（G/GEJ）腺癌患者的新适应症上市许可申请（sBLA）。这也是是百泽安®在中国递交的第10项上市许可申请。截至发稿，百济神州涨5.82%，报97.30港元，成交额0.48亿港元。6月21日，百济神州(06160)...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/742489.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/742489.html","article_id":"2245267136","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2245267136","pubTimestamp":1655862002,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，百济神州盘初高开高走，升超6%。这也是是百泽安在中国递交的第10项上市许可申请。截至发稿，百济神州涨5.82%，报97.30港元，成交额0.48亿港元。6月21日，百济神州宣布，NMPA已受理公司自主研发的抗PD-1抗体百泽安联合化疗，用于一线治疗肿瘤表达PD-L1的晚期或转移性胃或胃食管结合部腺癌患者的新适应症上市许可申请。本次sBLA的申报是百泽安在中国递交的第10项上市许可申请，此前，百泽安已获NMPA批准用于9项适应症的治疗。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688235":"百济神州","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","BK1161":"生物科技","BK1500":"做空集合股","BK4505":"高瓴资本持仓","BK4526":"热门中概股","BK4139":"生物科技","06160":"百济神州","BK4504":"桥水持仓","BK1583":"高瓴概念","BGNE":"百济神州","BK1588":"回港中概股"},"translate_title":"Hong Kong stocks changed Baekje Shenzhou (06160) rose 6% and successfully submitted the 10th domestic listing application for Leilizhu","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":1,"06160":1,"BGNE":1},"content_text":"智通财经APP获悉，百济神州(06160)盘初高开高走，升超6%。公司宣布，NMPA已受理百泽安®（替雷利珠单抗）联合化疗，用于一线治疗肿瘤表达PD-L1的晚期或转移性胃或胃食管结合部（G/GEJ）腺癌患者的新适应症上市许可申请（sBLA）。这也是是百泽安®在中国递交的第10项上市许可申请。截至发稿，百济神州涨5.82%，报97.30港元，成交额0.48亿港元。6月21日，百济神州(06160)宣布，NMPA已受理公司自主研发的抗PD-1抗体百泽安®（替雷利珠单抗）联合化疗，用于一线治疗肿瘤表达PD-L1的晚期或转移性胃或胃食管结合部（G/GEJ）腺癌患者的新适应症上市许可申请（sBLA）。本次sBLA的申报是百泽安®在中国递交的第10项上市许可申请，此前，百泽安®已获NMPA批准用于9项适应症的治疗。在海外，百泽安®用于治疗既往接受过化疗的晚期或转移性食管鳞状细胞癌（ESCC）患者的上市许可申请已获得FDA和EMA的受理，正在审评过程中。2021年1月，公司决定授权诺华在北美、欧洲和日本开发、生产和商业化百泽安®。目前，百泽安®在中国以外国家或地区尚未获批。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2245267136"}